Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Jacqueline D. Barrientos
ASH 2021: COVID Risk and Precautions for Patients With CLL
Published on December 21, 2021 Experts Discuss COVID Risk and Precautions for CLL Patients How can patients with CLL prepare for a safe holiday season? Are they at the same level of risk as earlier in the pandemic? Finally, what precautions do doctors recommend?
ASH 2021: Maintaining Quality of Life During the CLL Treatment Journey
View next Published on December 21, 2021 The Importance of Quality of Life During CLL Treatment Jacqueline Barrientos, MD, MS, of Northwell Health and Nicole Lamanna, MD, of Columbia University join Patient Power co-founder and CLL patient Andrew Schorr to discuss how CLL researchers and doctors are prioritizing quality of life during CLL treatment.
ASH 2021: Could Immunotherapy Lead to a Cure for CLL?
Published on December 16, 2021 New Developments in Immunotherapy for CLL Could we be on the path to an eventual cure for CLL? Deborah Stephens, DO, of the Huntsman Cancer Institute, Jacqueline Barrientos, MD, MS, of Northwell Health, and Nicole Lamanna, MD, of Columbia University join Patient Power co-founder and CLL survivor Andrew Schorr for a roundtable discussion about immunotherapy.
ASH 2021: Approved and Emerging Combination Therapies for CLL
Published on December 15, 2021 What Combination Therapies Are Available for Patients With CLL? Follow along as Patient Power co-founder and CLL survivor Andrew Schorr meets with Deborah Stephens, DO, of the Huntsman Cancer Institute, Jacqueline Barrientos, MD, MS, of Northwell Health, and Nicole Lamanna, MD, of Columbia University, for a roundtable discussion about new information on combination therapies that was presented at the American Society of Hematology (ASH) conference.
ASH 2021: Celebrating the Success of CLL Therapies
Published on December 14, 2021 Experts Discuss Successful Therapies and ASH 2021 News “Before the Bruton tyrosine kinase inhibitors, and ibrutinib was the first one of these, there weren't a lot of options for patients who had gone through multiple treatments for their CLL.” - Deborah Stephens, DO, Huntsman Cancer Institute.
Second Generation BTK Inhibitors for CLL
View next Published on September 3, 2021 What Are Second-Generation BTK Inhibitors? The approval of the first BTK inhibitor was a game changer for the treatment of CLL. In this video, Jacqueline Claudia Barrientos, MD, MS, of Northwell Health gives an overview of second-generation BTK inhibitors, their side effect profile, and how they differ from first-generation BTK inhibitors.
ASH 2020: CLL Treatment Overview and Addressing COVID Concerns
Published on December 14, 2020 Experts Share The Latest Developments in CLL Treatment and Patient Care What are the treatment options and newest developments in treatment research for chronic lymphocytic leukemia (CLL)? How do healthcare disparities affect access to CLL care? What should patients know about CLL and COVID-19?
Better CLL Treatments and Outcomes
View next Published on June 5, 2020 Making treatment decisions can be a challenge for any chronic lymphocytic leukemia (CLL) patient. Patient advocate Carol Preston is joined by Dr. Jacqueline Barrientos to answer questions from CLL patients and care partners. Watch to learn expert answers about treatments, skin rashes and CLL, and more. This program is sponsored by AbbVie, Inc., Genentech, Inc. and Adaptive Biotechnologies. These organizations have no editorial control.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Jacqueline D.
Contact Jacqueline D., search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack